BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 31, 2006
View Archived Issues
CV Therapeutics Gets FDA OK To Sell Ranexa In Angina
At last, the FDA cleared Ranexa (ranolazine extended-release tablets), the first new angina drug approved in the U.S. in more than 20 years. (BioWorld Today)
Read More
CombinatoRx's Osteo Drug Proves Beneficial In Phase II
Read More
Starting From No Activity Yields New Anti-Alzheimer's Chemical
Read More
CytRx Forming Subsidiary To Accelerate RNAi Work
Read More
Other News To Note
Read More